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Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is a leading cause of foodborne
illnesses worldwide and is a common serotype linked to hemorrhagic colitis and an
important cause of hemolytic uremic syndrome (HUS). Treatment of EHEC O157:H7
infections is complicated, as antibiotics can exacerbate Shiga toxin (Stx) production
and lead to more severe symptoms including HUS. To date, no vaccines have been
approved for human use, exposing a void in both treatment and prevention of EHEC
O157:H7 infections. Previously, our lab has shown success in identifying novel vaccine
candidates via bio- and immunoinformatics approaches, which are capable of reducing
bacterial colonization in an in vivo model of intestinal colonization. In this study, we
further characterized 17 of the identified vaccine candidates at the bioinformatics level
and evaluated the protective capacity of the top three candidates when administered
as DNA vaccines in our murine model of EHEC O157:H7 colonization. Based on
further immunoinformatic predictions, these vaccine candidates were expected to induce
neutralizing antibodies in a Th2-skewed immunological response. Immunization of
BALB/c mice with two of these candidates resulted in reduced bacterial colonization
following EHEC O157:H7 challenge. Additionally, immune sera was shown to prevent
bacterial adhesion in vitro to Caco-2 cells. Together, this study provides further validation
of our immunoinformatic analyses and identifies promising vaccine candidates against
EHEC O157:H7.
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INTRODUCTION
Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is a gram-negative bacteria, member of the
Shiga-toxin producing pathogroup of E. coli (STEC) strains. Infections with EHEC O157:H7 are
associated with diarrheal episodes, including severe manifestations such as hemorrhagic colitis and
hemolytic uremic syndrome (HUS) (Nguyen and Sperandio, 2012). Ingestion of E. coli O157:H7
bacteria is primarily through the consumption of contaminated food (animal and produce)
products and water. The E. coli O157:H7 serotype is responsible for ∼0.9 cases of hemorrhagic
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colitis per 100,000 in the United States, and an estimate
79,420 total cases each year (Marks et al., 2013). In addition,
E. coli O157:H7 infections result in a significant number
of hospitalizations each year; complications predominantly
affecting children and elderly patients (Marks et al., 2013).
According to a 2013 report by the United States Department of
Agriculture (USDA), E. coli O157:H7 alone cost ∼272 million
dollars in hospitalizations and corporate food-related losses (Batz
et al., 2014). Moreover, enteric infections caused by O157:H7 lead
to a 2–5% mortality rate in children with HUS (Banatvala et al.,
2001; Rangel et al., 2005). Worldwide, the highest rate of HUS
occurs in Argentina where 400 new cases are reported annually,
and the frequency of HUS ranges from 10 to 17 cases per 100,000
children (Rivas et al., 2006). This rate is an overwhelming 10-fold
difference compared to most developed countries (Rivas et al.,
2006).
E. coli O157:H7 infections are mediated primarily by the
interaction between intimin (Int) adhesin and its cognate
translocated intimin receptor (Tir) (Kenny et al., 1997; Deibel
et al., 1998). The type-III secretion system (T3SS) functions
in delivering Tir and other effector molecules into the host
cytoplasm of the gut epithelial cells, resulting in host cytoskeletal
rearrangement and the formation of distinct, pedestal-like
structures (McDaniel et al., 1995; Elliott et al., 1998; Campellone
et al., 2004). These changes are characteristic of a lesion known
as attaching and effacing (A/E), which are a hallmark in the
intimate attachment of bacteria to the mucosal epithelia (Nataro
and Kaper, 1998).
There are currently two EHEC vaccines available for animal
use; however, to date, there are no vaccines approved for use
in humans (Snedeker et al., 2012; Varela et al., 2013). EHEC
infections remain a significant clinical challenge, antibiotic use is
contraindicated due to the ability to exacerbate Shiga toxin (Stx)
production and increasing the risk of HUS (Karch et al., 1999;
Matsushiro et al., 1999). Consequently, it remains an important
task to identify vaccine candidates capable of reducing bacterial
colonization capabilities that will prevent further complications
in humans.
Our lab has previously developed an optimized bioinformatic
screening method to identify EHEC O157:H7 vaccine candidates
not present in commensal E. coli flora (García-Angulo et al., 2013,
2014; Kalita et al., 2014). Using a stepwise screening approach,
we down selected from the entire EHEC O157:H7 proteome
and identified priority vaccine candidates, which were chosen
based on desirable physiochemical properties, antigenicity, and
MHC affinity. We then validated our screening methodologies
in vivo by immunizing mice with pVAX-encoded candidates with
high, medium, and low predicted antigenicity. The candidates
of high predicted antigenicity produced higher antibody titers,
decreased bacterial shedding, and reduced cecal and large
intestinemurine colonization (Kalita et al., 2014). Taken together,
these observations suggest that these vaccine candidates are
capable of inducing neutralizing antibodies that can effectively
prevent the attachment of E. coli O157:H7 to intestinal epithelial
cells. It’s important to note that some of the high priority (HP)
candidates identified are predicted to play a role in the structure
or function of the T3SS (García-Angulo et al., 2014). Because the
T3SS is critical to EHEC O157:H7 virulence and pathogenesis,
the inclusion of these antigens into a subunit vaccine could prove
valuable in generating a protective immune response.
Our previous study tested randomly pooled candidates in
vivo and found that immunization with a truncated T3SS
structural escC, resulted in the most significant reduction in
bacterial load (García-Angulo et al., 2014). The escC gene (locus
AE005596_9) encodes for a structural protein of the T3SS that
forms a polymer ring spaning the bacterial outer membrane
(Sekiya et al., 2001; Spreter et al., 2009; Tree et al., 2009). In
our present study, we sought to identify comparable candidates
by screening the density of immunogenic epitopes within our
highly ranked proteins. By performing a mature epitope density
(MED) prediction, we were able to cluster candidates based on
similarities in putative immunogenic Th2 epitopes (MEDTh2).
This method allowed us to identify two new candidates, lomW
(locus AE005298_8), a gene ecoding a putative outer-membrane
protein belonging to the Lom precursor of a bacteriophage Bp-
933W, and escJ gene (locus AE005514_9), encoding a putative
lipoprotein associated with the T3SS. These candidates were
cloned in pVAX1 vector and administered intranasally to BALB/c
mice. Upon vaccination, we observed the largest increase in
sIgA levels from lomW in comparison to escC and escJ. While
no significant difference was detected in total IgG levels, we
did distinguish a significant reduction in bacterial adhesion to
intestinal epithelial cells in vitro and reduced colonization in a
murine model of EHEC O157:H7 infection. Our current study
aided in validating and characterizing novel E. coli O157:H7-
specific vaccine candidates, and defined important immune
parameters necessary to prevent intestinal disease caused by
E. coli O157:H7.
MATERIALS AND METHODS
Ethics Statement
All manipulations of E. coli strains were conducted in approved
and certified Biosafety Level 2 facilities at the University of Texas
Medical Branch (UTMB), and experiments were performed in
accordance with standard operating practices. The animal studies
were carried out in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol (IACUC #0709042B)
was approved by the Institution for Animal Care and Use
Committee at UTMB.
Bacterial Strains Culture Conditions
All bacterial strains used in this study were stored in 50% glycerol
at −80◦C. Liquid cultures were generated by inoculating Luria-
Bertani (LB) broth, with or without 50µg/mL streptomycin.
Liquid cultures were grown overnight at 37◦Cwith agitation. The
prototypical E. coli O157:H7 strain 86-24 was used for animal
challenge studies. E. coli O157:H7 wildtype strain EDL933 was
utilized for gene amplifications and bacterial adhesion assays.
E. coli strain DH5α (Life Technologies) was used for propagation
of strains bearing pVAX1 plasmid and was routinely grown in
LB broth and agar containing kanamycin (Sigma, 50µg/mL) for
plasmid selection.
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Immunoinformatic Analysis
We used NetMHC-II (Nielsen and Lund, 2009), NetCTL (Larsen
et al., 2007) and ABCPred (Saha and Raghava, 2006) to predict
the MHC class II, MHC class I and linear B-cell binding epitopes,
respectively, in EHEC O157:H7 specific proteins (further details
in García-Angulo et al., 2014; Kalita et al., 2014). Program
outputs reported the binding affinity (IC50) of individual epitopes
to various HLA alleles. Based on these IC50 values, all possible
9-mer epitopes from each protein were predicted as weak
(IC50 > 500 nM) or strong binding (IC50 > 50 nM). We selected
only strong binding peptides having a predicted IC50 value
<50 nM (used as threshold). To assess the potential to induce
a Th2-skewed protective response, we focused on NetMHCII
output consisting of six HLA-DP, six HLA-DQ, and 14 HLA-DR
alleles. We derived two parameters from the NetMHCII output:
a) average MHC Affinity (Avg-MA) for all epitopes in a given
protein sequence and b) mature epitope density (MEDTh2) score
using the formula below, where epitope length is core 9-mer
(Santos et al., 2013).
MEDTh2 =
Predictions
Chances
=
number of predicted epitopes X (50− Avg-MA)
protein sequence length− epitope length∗ + 1
(1)
This MEDTh2 score reflects aggregate T-cell (Th2) epitope
content. Higher scores indicate a better prediction for the
protective nature of the protein. Also, the number of alleles
bound by each protein was evaluated in order to target a larger
population coverage. A heatmap of Avg-MA against each HLA-
allele for all protein sequences was generated (Supplemental
Figure 1). A clustered image map (CIM) of a normalized
matrix was created that correlates Avg-MA of each allele
to different proteins. For each protein, mean and standard
deviation were calculated from their Avg-MA for all alleles. Z-
score transformation was calculated for each of the alleles by
subtracting each Avg-MA value by the row mean and dividing
by the row standard deviation (Kalita et al., 2013). Hierarchical
clustering of HP proteins was performed using an average-
linkage clustering algorithm based on their MEDTh2 scores.
DNA Vaccine Construction
Vaccine candidates were amplified from E. coli EDL933 genomic
DNA. Forward (Fw) and reverse (Rv) primer sequences
contained HindIII and XhoI restriction sites, respectively
(Supplemental Table 1). The 5′ end of Fw primers were
designed with a Kozak consensus sequence (ACCATGG) to
enhance transcription. Genes were amplified with Phusion R©
High Fidelity Polymerase (New England Biolabs) and ligated
into the eukaryotic expression vector pVAX1 (Invitrogen,
Life Technologies). Plasmids containing desired candidates
were verified by directional sequencing and transformed into
competent E. coli DH5α for propagation. For immunization
studies, plasmids were purified using the Endotoxin-free Giga Kit
(Qiagen) according to manufacturer’s instructions. DNA samples
were quantified using a Epoch Microplate Spectrophotometer
(BioTek) and stored at−20◦C.
Immunization and Sample Collection
Six to eight-week-old female BALB/c mice were obtained from
Charles River Laboratories and housed in a specific pathogen-
free barrier under biosafety level 2 conditions and allowed to
acclimate for 5 days prior to vaccination. Mice were divided
into 5 groups (n = 10 each), including pVAX (vector), lomW
(pVAX-10), escJ (pVAX-41), escC (pVAX-56), and combination
(pComb). Mice were anesthetized using isoflurane inhalation
and administered a prime and two boosts (days 0, 14, and 28)
intranasal (i.n.) immunization of ∼60µg DNA in Tris-EDTA.
Prime vaccinations were administered along with Cholera Toxin
(CT) as adjuvant (1µg/uL). In the case of the combination
vaccine, ∼20µg of each plasmid were mixed and administered
as a single vaccine. Fecal and sera samples were collected prior
to vaccination for determination of baseline antibody titers.
Fecal samples were collected following final boost to monitor
mucosal antibody titers. Briefly, fecal pellets were weighed and
diluted to 1 g/mL in PBS. After homogenization by vortexing,
fecal samples were then centrifuged at 4000 rpm for 10min.
Supernatants were stored at −20◦C prior to IgA measurement.
Sera samples were collected 2 weeks after prime and second
boost vaccination to monitor changes in antibody levels. Sera
was collected via retro-orbital bleeding and incubated at room
temperature for 30min to allow clotting. Sera was separated
from whole blood by centrifugation at 10,000 rpm for 10min.
Supernatants were collected and stored at −80◦C prior to
enzyme-linked immunosorbent assay (ELISA).
Infection
Two weeks after the second boost, all mice were challenged with
a dose of 5 × 109 CFU of streptomycin resistant E. coli O157:H7
strain 86-24 via gavage (400µL). Food was restricted 12 h
before infection but was administered ad libitum throughout the
remainder of the study. Two hours prior to challenge, mice were
injected intraperitoneally with cimetidine (50mg/kg, Sigma) to
reduce stomach acidity. Fecal samples were collected daily for 7
days to assess bacterial shedding. Fecal pellets were homogenized
in phosphate-buffered saline (PBS), serially diluted, and plated
on MacConkey agar plates containing streptomycin (25µg/mL)
and incubated at 37◦C. To enumerate bacterial colonization in
gastrointestinal tract, mice were euthanized, and ceca and large
intestines were removed. Organs were homogenized in 1mL
PBS, serially diluted and plated on MacConkey agar containing
streptomycin.
ELISA
Total IgG and IgA responses were determined using Ready-set-
Go! ELISA kits (EBioscience) and were performed according
to manufacturer’s instructions. To determine immunoglobulin
levels, polystyrene 96-well high-binding ELISA plates (Nunc,
Denmark) were coated overnight with capture IgG or IgA
antibody at 4◦C. The plates were washed 2x with PBS containing
0.05% Tween 20 (PBS-T) prior to blocking in 2X Assay Buffer.
For IgG, the serum samples were diluted (1:1000 and 1:10,000)
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in 1X Assay Buffer. Similarly, for IgA levels, samples were
diluted (1:2 and 1:4) in 1X Assay Buffer. Following incubation,
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG,
or goat anti-mouse IgA was diluted in 1X Assay Buffer
(1:250) and added to ELISA plates to determine IgG and IgA
concentration, respectively. Plates were incubated with agitation
for 3 h at room temperature, followed by washing. A total of
100µL of tetramethylbenzidine (TMB) was added to each well
and incubated at room temperature for 15min. The reaction was
stopped using 100 uL of 2N H2SO4 and plate was read at 450 nm
(Biotech Microplate Spectrophotometer).
Bacterial Adhesion Assay
Caco-2 cells (ATCC R© HTB-37TM) were maintained at 37◦C
with 5% CO2 in complete HTB-37 medium. Complete HTB-37
media consisted of Eagle’s Minimum Essential Medium (EMEM,
GIBCO) supplemented with 2mM glutamine, 1mM sodium
pyruvate, 1X non-essential amino acids, penicillin-streptomycin
(100U/ml, 100µg/ml), and 10% fetal bovine serum. For adhesion
assays, 12-well plates were seeded with 105 cells per well
and incubated as described above to achieve 80% confluence.
Approximately 1 h prior to infection, the monolayer was washed
twice with 1ml PBS prior to addition of 1ml medium containing
no supplements. Fresh bacterial culture of E. coli O157:H7 strain
EDL933 was grown in LB overnight at 37◦C prior to infection.
Bacterial culture was diluted in LB (1:100) and incubated at
37◦C, shacking, until culture reached an OD600 of 1.0. Culture
was pelleted at 5000 × g for 5min, resuspended in PBS (Ca2+
and Mg2+ free), and plated for input bacterial load. Remaining
bacteria was incubated with immune or naïve sera (5 and 10%)
for 45min at 37◦C with agitation. At this time, media was
removed and replaced with 1ml fresh media containing 107
bacterial cells (multiplicity of infection [MOI], 100). Inoculated
monolayers were incubated for 3 h at 37◦C with 5% CO2. After
incubation, cells were washed three times with PBS prior to
addition of 200µl of 0.1% Triton X-100 in PBS. Wells were
incubated at 37◦C until cell monolayer detached from the plate.
Monolayers were homogenized by pipetting, then samples were
serially diluted and plated onto LB agar. The percentage of
bacteria recovered was calculated as the number of CFU/ml
recovered divided by the input CFU/ml to account for slight
variances in input between groups.
Statistical Analysis
Statistical significance between control and vaccinated groups
was assessed using GraphPad software. One-way analysis of
variance (ANOVA) and Student t test were used to analyze
the data for colonization and antibody response, respectively.
Adhesion assay experiments were repeated in triplicate. Bacteria
recovered were normalized to the mean percentage of the
bacteria inoculated and the groups were compared using one-way
ANOVA followed by Kruskal-Wallis posthoc test. P < 0.05 were
considered significant.
RESULTS
Clustering of Vaccine Candidates by
Immunoinformatic Analysis
Figure 1A provides a schematic representation of Th2-oriented
epitope prediction and selection of seventeen, potentially
protective, high-priority (HP) vaccine candidates in EHEC
O157:H7 (García-Angulo et al., 2014). The distribution of high-
binding epitopes across numerous HLA alleles is depicted in a
heatmap (Supplemental Figure 1). This heatmap highlights allele
coverage, with proteins exhibiting increased allele coverage, and
thus more likely to induce an effective immune response in a
heterogenous population. While the majority of high priority
(HP) proteins have high MEDTh2 scores (above 10, Figure 1B),
there is selective binding across the array of HLA alleles. For
example, while lomW showed a high predictive binding affinity
toward DQ5 and DRB6 alleles, the escJ epitopes may bind more
strongly to DP4 as compared to other gene products. The data in
panel 1B was used to derive a dendrogram (Figure 2) to further
highlight protein clustering based on MEDTh2 score. Based on
FIGURE 1 | Classification of identified candidates. (A) Schematic representing prediction strategy for candidate selection of HP candidates. (B) Table showing
individual candidates along with their compiled MEDTh2 score and allele coverage across 17 high-priority candidates. The input to the equation was MHC-II prediction
results (NetMHCII) only. Hence, it is expected to provide us with Th2-oriented inference.
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FIGURE 2 | Dendrogram of vaccine candidates. Clustering of candidates
based on Mature Epitope Density (MED) Score. Selected candidates (green),
their compiled MEDTh2 score (red) and the number of HLA alleles covered
based (black) are highlighted.
our previous study that tested a pool of three randomly selected
HP candidates, immunization with truncated escC resulted in
themost significant reduction in bacterial colonization. However,
that study utilized only the second half of the gene as a vaccine
target instead of the entire gene, because we had problems
to clone it. In our present study, we were successfully able
to clone the full-length escC gene. The goal of this study
was to examine the protective capacity of whole escC gene
together with two closely related genes (lomW and escJ). In
summary, candidates were selected based on MEDTh2 scores,
allele coverage, physiochemical features, and predicted function.
Bacterial Colonization in Immunized Mice
with DNA Vaccine
BALB/c mice were immunized with the DNA vaccine candidates
as desbribed in Material and Methods. Two weeks after the
last immunization, animals were challenged with a dose of 5 ×
109 CFU of streptomycin-resistant E. coli O157:H7 strain 86-
24 via gavage. Seven days post-challenge, large intestines and
ceca were collected to enumerate bacterial colonization. The
bacterial load in the gastrointestinal tract (Figure 3) indicates
bacterial reduction in mice immunized with the three tested
candidate groups lomW (pVAX-10), escJ (pVAX-41), escC
(pVAX-56) compared to pVAX-only immunized group. When a
combination of all three (pComb) candidates were administered,
the reduction in colonization was minimum. Immunization with
lomW (pVAX-10) resulted in the greatest reduction in bacterial
colonization in the large intestine (p = 0.0423) (Figure 3A).
A similar trend is observed in cecum colonization, despite no
statistical significance (Figure 3B).
Immune Response of Mice Receiving the
DNA Vaccine
Fecal samples collected 2 weeks post-immunization were used
to measure sIgA production. Mice immunized with lomW
produced the highest levels of total sIgA when compared to
unimmunized mice (baseline), mice immunized with pVAX1
alone, or any of the other immunization groups, though
no statistical significance was observed (Figure 4A). Similarly,
escC was also shown to induce increased sIgA production.
Furthermore, sera collected from immunized mice 2 weeks after
the last immunization was used to measure total IgG antibodies.
Unlike sIgA, there appears to be no observable differences in
immunoglobulin production between the immunization groups
(Figure 4B).
Bacterial Adherence Inhibition by Sera
To further characterize the antibodies produced after
vaccination, we analyzed the capacity of immune sera to
prevent the adherence in vitro of E. coli O157:H7 to human
intestinal epithelial cells (Caco-2). Wild-type E. coli O157:H7
strain EDL933 was incubated with pooled sera (n = 3)
from immunized mice (5 and 10% concentration) at an MOI
of 100 prior to infection of Caco-2 cells. We observed the
most significant reduction in bacterial adherence from lomW
(p = 0.0466) and escC (p = 0.0029) immunized mice sera at
10%, and from lomW (p = 0.0466) and pComb (p = 0.0143)
at 5% concentration (Figures 5A,B). We noticed a decrease in
the percent bacterial adherence from all groups at 5% compared
to 10% sera. Also, we noticed a reduction in bacterial adherence
by sera from escJ and pComb compared to control groups at
both concentrations, but this reduction did not reach statistical
significance (Figures 5A,B). The ability of sera to inhibit
bacterial adherence in vitro to intestinal epithelial cells suggest
the possibility of some specificity of the sera while recognizing
surface-exposed proteins present on EHEC O157:H7 wild-type
strain EDL933.
DISCUSSION
Enterohemorrhagic E. coli (EHEC) O157:H7 is a foodborne
pathogen and one of the leading causative agents of hemorrhagic
colitis worldwide. Because Stx production can be intensified by
the administration of antibiotics and is associated with more
severe complications, there is a significant need for a human
vaccine that can have a positive impact in endemic regions and
during outbreaks. To follow up with our vaccine selection, we
conducted an immunoinformatic analysis on high-priority (HP)
candidates and clustered them to select highly immunogenic
candidates with MHC-I, MHC-II, and B-cell epitopes. From our
previous experiments that utilized a C-terminal tructated escC
gene, we noticed a significant decrease in bacterial colonization
in both the large intestine and cecum of infected mice. However,
in our present study, we noticed that bacterial colonization of
mice immunized with the full-length escC gene resulted in a
less significant reduction compared to the other two candidates
tested. This observation may be attributed to the fact that the
second half of the gene contains a greater number of epitopes
and/or a larger immunodominant segment, that might not be
accessible when the full length protein is expressed. However, our
present results suggest that immunization with HP candidates
identified by the bioinformatic analysis and clustered based on
a Th2-skewed immunological response can lead to a bacterial
reduction in the large intestine of infected mice. We have
identified a putative outer membrane protein Lom precursor
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FIGURE 3 | Bacterial counts in infected mice with EHEC O157:H7. Bacterial colonization of large intestine (A) and cecum (B) segments as collected from mice
vaccinated with pVAX1, lomW (pVAX-10), escJ (pVAX-41), escC (pVAX-56), and pComb followed by challenge with 5× 109 CFU of EHEC O157:H7. Bacterial counts
are represented as CFU per gram of tissue. Means ± the SEM of the CFU/g from 10 mice presented and an asterisk (*) indicates statistical significance as defined
(p < 0.05).
FIGURE 4 | Immune response from mice immunized with pVAX candidates. Graphs show secreted immunoglobulin A (A) and IgG (B) total levels, 2 weeks
after last immunization. Mean IgA levels were measured from fecal samples of three immunized mice with lomW (pVAX-10), escJ (pVAX-41), escC (pVAX-56), or
pComb. Feces collected prior to immunization (baseline) and of mice immunized with pVAX1 were used as controls. The results are expressed as means ± the SEM
of triplicate values obtained from three mice from each group. Statistical significance was defined as (p < 0.05). (B) Sera collected from mice immunized with vaccine
candidates was used to measure total IgG antibodies by ELISA. The results are expressed as means ± of the SEM of triplicate values from three mice in each group.
from bacteriophage BP-933W (lomW), when expressed from a
eukaryotic expression plasmid, was able to significant reduce
murine intestinal colonization (p = 0.0423). Immunization with
lomW (pVAX-10) was also shown to induce the highest increase
in sIgA antibodies compared to baseline levels. The correlation
between high sIgA and decreased colonization suggests that
sIgA plays an important role in preventing EHEC O157:H7
colonization in the intestinal tract. Moreover, lomW has a
13 HLA allele coverage, theoretically allowing for more broad
protection.While escC (pVAX-56) was not as protective as lomW,
when tested in vivo, sera from immunizedmice from both groups
was capable of reducing bacterial adherence in vitro to primary
epithelial cells at 10% sera concentration. Specifically, sera from
lomW (p = 0.0466) and escC-immunized mice (p = 0.0029)
was able to provide the most significant inhibition of bacterial
adherence to human epithelial cells. These finding suggests that
EscC protein antigens may not be readily accessible when the
bacteria is in the intestinal environment, but might still be
effective during in vitro culture conditions. While we were not
able to observe any significant differences in total IgG levels, the
role of individual IgG isotypes inmediating protection has not yet
been characterized and warrants further attention. The moderate
IgG and sIgA antibody titer in response to immunization with
pVAX1 alone could, in part, be attributed to variations in
individual mouse antibody levels. While reporting individual
antibody levels might be a more accurate representation of
the results, these levels can vary considerably. Moreover, when
previously tested as a truncated gene portion, escCwas protective.
However, in the current study, immunization with the full-length
gene provided no significant reduction in bacterial colonization
in vivo, but was capable of reducing bacterial adherence in vitro.
These results suggest the possibility that the second portion of
the truncated gene may be a good target for vaccine design
because its concentration of immunogenic epitopes that might
be essential for inducing protective antibody production. As
previously stated, it is plausible to propose that expression of the
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FIGURE 5 | Bacterial adhesion reduction by immune sera from vaccinated mice. EHEC O157:H7 serotype EDL933 was incubated with 10% (A) or 5% (B)
pooled sera (n = 3) from immunized mice with lomW (pVAX-10), escJ (pVAX-41), escC (pVAX-56), and –pComb in PBS and further incubated with Caco-2 cells at an
MOI of 1:100 for 3 h to allow adherence. Sera from pVAX1 immunized mice as well as bacteria alone served as control groups. Bacterial adherence is shown as a
percentage of bacteria recovered after incubation. Results are shown as percent adherence and as means ± of the SEM of triplicate values obtained from individual
incubation well of bacteria with Caco-2 cells, and an asterisk (*) indicates statistical significance as defined (p < 0.05), **p < 0.005.
full-length gene might mask immunogenic epitopes or reduce
efficacy in antigen presentation.
Currently, one of the most significant obstacles limiting the
advancement of a vaccine against EHECO157:H7 is the potential
to disrupt intestinal commensal flora in humans. However,
in our selection of candidates and current vaccination study,
we took careful steps to avoid selecting genes common to
commensal flora. Specifically, we performed genome-wide E. coli
comparisons to identify genes specific to the most prevalent
EHEC O157:H7 serotypes and not present in commensal
bacteria. This study combines an in silico approach, together
with in vivo vaccination studies, to evaluate the effectiveness of
potential candidates. While the use of a DNA vector as a vaccine
is an efficient method to screen a pool of candidates, future
studies will focus on evaluating proteins in combination with
various platforms and adjuvants to achieve increased protection.
Taken together, this study expands the current pool of potential
vaccine candidates and provides an important foundation for
continued optimization studies toward the development of an
effective EHEC O157:H7 vaccine.
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